Navigation Links
BrainStorm Announces Treatment of Final Patient in US Multicenter Double Blinded Phase 2 ALS Trial
Date:10/7/2015

HACKENSACK, N.J. and PETACH TIKVAH, Israel, Oct. 7, 2015 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the final patient has been treated in its multicenter Phase 2 clinical trial investigating the company's proprietary NurOwn™ stem cell technology. The trial is a double blind, placebo-controlled, clinical trial which targeted enrollment of 48 patients with Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease.

The study was designed to evaluate the safety and efficacy of transplantation of Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors ("MSC-NTF" or NurOwn™). The trial is being conducted at the Massachusetts General Hospital (MGH) in Boston, MA, University of Massachusetts Memorial (UMass) Hospital in Worcester, MA, and Mayo Clinic in Rochester, Minnesota.

"We are pleased to have successfully completed all transplantations," said principal investigator, Prof. Anthony J. Windebank, MD, "In six months, we expect to complete follow-up visits on the last patients, and we are looking forward to seeing the analysis of the complete results.  The initial safety profile has been excellent and the treatment generally well-tolerated – which is a primary goal of the study."

"We are proud to announce the completion of dosing of this multicenter study on schedule, which is one of the company's most important milestones to date. Importantly, this is the first trial to compare NurOwn with placebo," said Chaim Lebovits, CEO of BrainStorm. "We are extremely thankful for having the opportunity to collaborate with three top-tier US medical centers – MGH, UMass and Mayo Clinic. And we would like to express our special appreciation and thanks to our team of PI's – Prof. Robert H. Brown, MD, DPhil, Chair of the Neurological Department at UMass, Prof. Merit Cudkowicz, MD, MSc, Chair of the MGH Neurological Clinical Research Institute (NCRI), and Prof. Anthony J. Windebank, MD, Head of the Regenerative Neurobiology Laboratory in the Department of Neurology at Mayo Clinic."          

About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University.  NurOwn® has been administered to over 30 patients with ALS in clinical trials conducted in Israel, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States.  For more information, visit the Company's website at www.brainstorm-cell.com.

Safe Harbor Statement
Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements.  The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov.  These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements.  These forward-looking statements are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTS

BrainStorm Cell Therapeutics Inc.
201-488-0460
info@brainstorm-cell.com

Investors:
LifeSci Advisors, LLC
Michael Rice
Phone: 646-597-6979
mrice@lifesciadvisors.com

Logo - http://photos.prnewswire.com/prnh/20141006/150511


'/>"/>
SOURCE BrainStorm Cell Therapeutics Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Cannabis Science Highlights Additional Attendees at the Washington DC, African Union, CFA African Healthcare Infrastructure Forum and Brainstorm on February 6, 2015
2. Latest Updates on Health Care Sector: Special Research on bluebird bio, Brainstorm, CASI Pharmaceuticals, Celladon, and Cellular Dynamics
3. BrainStorm Cell Therapeutics to Report Fourth Quarter and Full Year 2014 Financial Results on Thursday, March 26
4. Pharmagen Announces First Quarter 2013 Results
5. Aoxing Pharmaceutical Company, Inc. Announces Financial Results For Third Quarter Of 2013 Fiscal Year
6. Vasomedical Announces Financial Results for the First Quarter of 2013
7. TSI Announces 2013 Respiratory Protection Roadshow Training Dates and Locations
8. Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeants Board of Directors
9. Active Life Announces $500K Follow On Series A Investment - Tech Coast Angels Re-up
10. Pentec Health Announces Limited Voluntary Recall of Certain Compounded Prescription Therapies for Renal Patients
11. DebMed Announces US Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2021)... ... March 29, 2021 , ... The University of Texas Health Science Center ... San Antonio Multispecialty and Research Hospital, a destination center for research and treatment of ... In a nod to the COVID-19 pandemic, the ceremony was held virtually. , William ...
(Date:3/30/2021)... ... March 29, 2021 , ... Iora Health ... primary care, has partnered with Devoted Health , one of the fastest-growing ... across Maricopa County and provides seniors with the highest-quality care and experience possible, ...
(Date:3/30/2021)... CITY (PRWEB) , ... March 29, 2021 , ... ... has joined the Vaccine Credential Initiative (VCI), a group bringing together leading health ... record of vaccination status, based on open, interoperable standards. By joining the VCI ...
Breaking Medicine Technology:
(Date:3/30/2021)... , ... March 29, 2021 , ... ... the 21st Century , A Virtual Workshop Presented by WCG FDAnews and Cerulean ... 4:30 pm EDT, https://wcg.swoogo.com/modern-sop-and-quality-systems , Are one’s SOPs written for the ...
(Date:3/30/2021)... ... March 29, 2021 , ... According to data released ... reproductive age (13-44) in need of publicly funded contraception live in counties impacted by ... Colorado’s 64 counties have lost some of their Title X resources. , The ...
(Date:3/30/2021)... ... March 29, 2021 , ... Health Literacy Innovations (HLI), a ... confusion due to low health literacy today announces a new partnership with the ... work with ACAP’s member Safety Net Health Plans, those that provide comprehensive health ...
(Date:3/30/2021)... ... ... Dr. Colin Campbell is proud to announce the 1 year anniversary in their new state ... internal medicine and is a primary care specialist who has been practicing for 23 years. ... keep South Jersey healthy one patient at a time. , “Over the past year, Dr. ...
(Date:3/30/2021)... ... March 30, 2021 , ... The COVID-19 ... and survivors; their families; and their caregivers. Crossroads4Hope is addressing the needs of ... emotional support system, MyGo2Support, which meets needs of people impacted by cancer, no ...
Breaking Medicine News(10 mins):